Strategic Expansion Frontage is rapidly expanding its global footprint with new offices in the United States and China and an acquired Teddy Lab in China, signifying a broader capacity to support international clinical development and regulatory submissions.

Leadership Elevation Recent promotions of senior leaders in bioanalytical services and corporate quality assurance IT underscore a focus on strengthening quality, data integrity, and analytical capabilities to attract larger pharma and biotech partnerships.

Integrated CRO-CDMO As a full-service CRDMO with capabilities spanning discovery through early phase manufacturing and centralized labs, Frontage presents a one-stop option for sponsors seeking streamlined progression of molecules across multiple regions.

Regulatory Readiness FDA registration and multi-region experience, plus ongoing quality and IT enhancements, position Frontage as a reliable partner for regulatory submissions in the US, EU, China, and other markets, appealing to sponsors aiming for global trials.

Strategic Partnerships Recent MOU with GCCL and international lab capabilities suggest a growth strategy centered on expanding collaboration networks and enhancing global clinical trial analytics and central lab support for international studies.